The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
暂无分享,去创建一个
[1] D. Selkoe. Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. , 1989, Cell.
[2] D. Pollen,et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.
[3] F. Gage,et al. Neural consequences of enviromental enrichment , 2000, Nature Reviews Neuroscience.
[4] K. Blennow,et al. Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease , 2010, PloS one.
[5] E. Bigio,et al. Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.
[6] P. Siekevitz. The postsynaptic density : A possible role in long-lasting effects in the central nervous system ( theory / protein modifications / structure change / synaptic strength ) , 2022 .
[7] Susan M Resnick,et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.
[8] R. Anwyl,et al. Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5 , 2004, The Journal of Neuroscience.
[9] A. Jasiński,et al. Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. , 2010, Acta neurochirurgica. Supplement.
[10] Jill A. White,et al. Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation , 2005, Neurobiology of Disease.
[11] Seiji Nishino,et al. Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.
[12] S. M. de la Monte,et al. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. , 2008, Journal of Alzheimer's disease : JAD.
[13] P. Riederer,et al. Diabetes Type II: A Risk Factor for Depression–Parkinson–Alzheimer? , 2011, Neurotoxicity Research.
[14] R. Martins,et al. Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype , 2000, Annals of the New York Academy of Sciences.
[15] M. White. Insulin Signaling in Health and Disease , 2003, Science.
[16] P. Greengard,et al. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses , 2005, Neurobiology of Disease.
[17] C. Heizmann,et al. Site-Specific Blockade of RAGE-Vd Prevents Amyloid-β Oligomer Neurotoxicity , 2008, The Journal of Neuroscience.
[18] Allan I. Levey,et al. Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.
[19] Shaomin Li,et al. Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors , 2011, The Journal of Neuroscience.
[20] R. Malinow,et al. AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss , 2006, Neuron.
[21] S. Hoyer. Risk factors for Alzheimer's disease during aging. Impacts of glucose/energy metabolism. , 1998, Journal of neural transmission. Supplementum.
[22] P. Riederer,et al. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. , 2010, Journal of Alzheimer's disease : JAD.
[23] M. Sheng,et al. PDZ domain proteins of synapses , 2004, Nature Reviews Neuroscience.
[24] M. Pericak-Vance,et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.
[25] O. Arancio,et al. Preparation of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices. , 2010, Journal of visualized experiments : JoVE.
[26] D. Selkoe. The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. , 2000, Neurologic clinics.
[27] N. Chauhan. Intracerebroventricular passive immunization with anti‐oligoAβ antibody in TgCRND8 , 2007, Journal of neuroscience research.
[28] R. Hepler,et al. Solution State Characterization of Amyloid β-Derived Diffusible Ligands , 2006 .
[29] E. Cavalheiro,et al. Activation of D1/D5 Dopamine Receptors Protects Neurons from Synapse Dysfunction Induced by Amyloid-β Oligomers* , 2010, The Journal of Biological Chemistry.
[30] Peter Schönknecht,et al. Type II diabetes in mild cognitive impairment and Alzheimer's disease: results from a prospective population-based study in Germany. , 2009, Journal of Alzheimer's disease : JAD.
[31] A. Aguzzi,et al. Supplementary figure legends , 2010 .
[32] D. Price,et al. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[33] Tao Wang,et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model , 2010, Molecular Neurodegeneration.
[34] M. Kennedy,et al. Signal-processing machines at the postsynaptic density. , 2000, Science.
[35] W. Klein,et al. Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5 , 2010, Neuron.
[36] C. Finch,et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[37] R. Balázs,et al. β-Amyloid-(1–42) Impairs Activity-dependent cAMP-response Element-binding Protein Signaling in Neurons at Concentrations in Which Cell Survival Is Not Compromised* , 2001, The Journal of Biological Chemistry.
[38] E. Ziff. Enlightening the Postsynaptic Density , 1997, Neuron.
[39] Ian Parker,et al. Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦ , 2005, Journal of Biological Chemistry.
[40] M. Pericak-Vance,et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[41] N. Inestrosa,et al. Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses , 2010, Proceedings of the National Academy of Sciences.
[42] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[43] J. Hardy,et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.
[44] Inflammation in Alzheimer’s Disease , 2001 .
[45] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[46] C. Bramham. Local protein synthesis, actin dynamics, and LTP consolidation , 2008, Current Opinion in Neurobiology.
[47] L. Reagan,et al. Insulin signaling effects on memory and mood. , 2007, Current opinion in pharmacology.
[48] J. Deussing,et al. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices , 2011, Neuropharmacology.
[49] Ling Li,et al. Intake of Sucrose-sweetened Water Induces Insulin Resistance and Exacerbates Memory Deficits and Amyloidosis in a Transgenic Mouse Model of Alzheimer Disease* , 2007, Journal of Biological Chemistry.
[50] 松崎 尊信. Insulin resistance is associated with the pathology of Alzheimer's disease : the Hisayama study , 2010 .
[51] Steven A. Johnson,et al. Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress , 1995, Experimental Neurology.
[52] W. Klein,et al. The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. , 2009, The American journal of pathology.
[53] B. Kriem,et al. Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3. , 2006, The Journal of biological chemistry.
[54] P. Keller,et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.
[55] S. Woods,et al. Intracerebroventricular insulin enhances memory in a passive-avoidance task , 2000, Physiology & Behavior.
[56] D. Bennett,et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.
[57] J. Malter,et al. FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein , 2007, PLoS biology.
[58] A. Scheibel,et al. Progressive dendritic changes in aging human cortex , 1975, Experimental Neurology.
[59] Y. Sheline,et al. Memory improvement following induced hyperinsulinemia in alzheimer's disease , 1996, Neurobiology of Aging.
[60] W. Klein,et al. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. , 2009, CNS & neurological disorders drug targets.
[61] K. Kawahara,et al. Primary Type 2 Microglia by Rat 42 - 1 -Amyloid Peptide b Oligomeric IL-4-Induced Selective Clearance of , 2008 .
[62] Y. Zhong,et al. PI3 kinase signaling is involved in Aβ-induced memory loss in Drosophila , 2010, Proceedings of the National Academy of Sciences.
[63] I. Hakker,et al. Aβ42 Mutants with Different Aggregation Profiles Induce Distinct Pathologies in Drosophila , 2008, PloS one.
[64] S. Strittmatter,et al. Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein , 2010, The Journal of Neuroscience.
[65] S. Craft,et al. The Role of Insulin Resistance in the Pathogenesis of Alzheimer’s Disease , 2003, CNS drugs.
[66] M. Abbott,et al. The Insulin Receptor Tyrosine Kinase Substrate p58/53 and the Insulin Receptor Are Components of CNS Synapses , 1999, The Journal of Neuroscience.
[67] N. Chattipakorn,et al. Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. , 2011, Life sciences.
[68] Takashi Morihara,et al. Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.
[69] Sanjay Asthana,et al. Insulin Metabolism in Alzheimer’s Disease Differs According to Apolipoprotein E Genotype and Gender , 1999, Neuroendocrinology.
[70] W. Klein,et al. Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.
[71] Julie Harris,et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model , 2011, Nature.
[72] J. D. McGaugh,et al. Inhibition of Activity-Dependent Arc Protein Expression in the Rat Hippocampus Impairs the Maintenance of Long-Term Potentiation and the Consolidation of Long-Term Memory , 2000, The Journal of Neuroscience.
[73] J. Unger,et al. Insulin receptors and signal transduction proteins in the hypothalamo-hypophyseal system: a review on morphological findings and functional implications. , 1998, Histology and histopathology.
[74] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[75] M. Beal,et al. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[76] W. Klein,et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[77] K. Zahs,et al. Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.
[78] H. Allain,et al. Treatment of the mild cognitive impairment (MCI) , 2007, Human psychopharmacology.
[79] Geeta S. Paranjape,et al. Amyloid-beta(1-42) fibrillar precursors are optimal for inducing tumor necrosis factor-alpha production in the THP-1 human monocytic cell line. , 2009, Biochemistry.
[80] D. Selkoe,et al. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.
[81] M. Szyf,et al. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. , 2010, Journal of Alzheimer's disease : JAD.
[82] Heike Wulff,et al. Amyloid-β Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial Neurotoxicity* , 2010, The Journal of Biological Chemistry.
[83] T. Tokuda,et al. High-molecular weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients , 2010, Alzheimer's & Dementia.
[84] D. Porte,et al. Localization of insulin receptor mRNA in rat brain by in situ hybridization. , 1990, Endocrinology.
[85] H. Ulrich,et al. Peptide Blockers of the Inhibition of Neuronal Nicotinic Acetylcholine Receptors by Amyloid β* , 2005, Journal of Biological Chemistry.
[86] Patrick R Hof,et al. Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[87] Thomas W. Mühleisen,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.
[88] E. Rojas,et al. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[89] H. Lin,et al. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[90] W Blaine Stine,et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. , 2002, Brain research.
[91] Adriana B Ferreira,et al. β-Amyloid-induced Dynamin 1 Degradation Is Mediated by N-Methyl-D-Aspartate Receptors in Hippocampal Neurons* , 2006, Journal of Biological Chemistry.
[92] C. Finch,et al. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[93] M. Brownstein,et al. Insulin and insulin receptors in rodent brain. , 1981, Diabetologia.
[94] A. Ott. Risk of dementia: The Rotterdam Study , 1997 .
[95] S. Ferreira,et al. Soluble Protein Oligomers as Emerging Toxins in Alzheimer′s and Other Amyloid Diseases , 2007 .
[96] R. Trullas,et al. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. , 2010, Cell calcium.
[97] J. Born,et al. Improving Influence of Insulin on Cognitive Functions in Humans , 2001, Neuroendocrinology.
[98] L. Mucke,et al. Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.
[99] K. Kawahara,et al. IL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat Primary Type 2 Microglia1 , 2008, The Journal of Immunology.
[100] G. Wilcock,et al. Hyperinsulinaemia and Alzheimer's disease. , 1994, Age and ageing.
[101] A. Draguhn,et al. Amyloid β Oligomers (Aβ1–42 Globulomer) Suppress Spontaneous Synaptic Activity by Inhibition of P/Q-Type Calcium Currents , 2008, The Journal of Neuroscience.
[102] E. Sigurdsson,et al. Murine models of Alzheimer's disease and their use in developing immunotherapies. , 2010, Biochimica et biophysica acta.
[103] E. Bigio,et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.
[104] N. Arispe. Architecture of the Alzheimer's A beta P ion channel pore. , 2004, The Journal of membrane biology.
[105] O. Arancio,et al. Phospholipase D2 Ablation Ameliorates Alzheimer's Disease-Linked Synaptic Dysfunction and Cognitive Deficits , 2010, The Journal of Neuroscience.
[106] C. Cotman,et al. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. , 1991, European journal of pharmacology.
[107] J. Luchsinger. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. , 2008, European journal of pharmacology.
[108] B. Kriem,et al. Microtubule-associated Protein MAP1A, MAP1B, and MAP2 Proteolysis during Soluble Amyloid β-Peptide-induced Neuronal Apoptosis , 2006, Journal of Biological Chemistry.
[109] C. Kahn,et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene , 1994, Nature.
[110] S. Deadwyler,et al. Experience-Dependent Regulation of the Immediate-Early Gene Arc Differs across Brain Regions , 2003, The Journal of Neuroscience.
[111] T. Wyss-Coray,et al. The p75 Neurotrophin Receptor Promotes Amyloid-β(1-42)-Induced Neuritic Dystrophy In Vitro and In Vivo , 2009, The Journal of Neuroscience.
[112] D. Alkon,et al. Insulin and the insulin receptor in experimental models of learning and memory. , 2004, European journal of pharmacology.
[113] B. Hyman,et al. Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.
[114] Claudio Soto,et al. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. , 2006, Trends in biochemical sciences.
[115] Xiongwei Zhu,et al. Insulin is a two-edged knife on the brain. , 2009, Journal of Alzheimer's disease : JAD.
[116] M. Gobbi,et al. Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein , 2010, Proceedings of the National Academy of Sciences.
[117] M. Brownstein,et al. Insulin and insulin receptors in rodent brain , 1981, Diabetologia.
[118] N. Arispe. Architecture of the Alzheimer’s AβP Ion Channel Pore , 2003, The Journal of Membrane Biology.
[119] M. Eckenhoff,et al. Inhaled Anesthetic Enhancement of Amyloid-&bgr; Oligomerization and Cytotoxicity , 2004, Anesthesiology.
[120] C. Bouras,et al. Down patients: Extracellular preamyloid deposits precede neuritic degeneration and senile plaques , 1989, Neuroscience Letters.
[121] N. Ferguson,et al. Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils , 2010, The Journal of Neuroscience.
[122] R. Panizzutti,et al. Aβ oligomers induce glutamate release from hippocampal neurons. , 2011, Current Alzheimer research.
[123] P. Greengard,et al. Regulation of NMDA receptor trafficking by amyloid-beta. , 2005, Nature neuroscience.
[124] T. W. Smith,et al. Optic nerve damage in shaken baby syndrome: detection by beta-amyloid precursor protein immunohistochemistry. , 2000, Archives of pathology & laboratory medicine.
[125] C. Cotman,et al. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. , 1991, Brain research.
[126] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[127] W. B. Stine,et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. , 1995, Experimental neurology.
[128] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[129] E. Leznik,et al. Microglial Receptor for Advanced Glycation End Product-Dependent Signal Pathway Drives β-Amyloid-Induced Synaptic Depression and Long-Term Depression Impairment in Entorhinal Cortex , 2010, The Journal of Neuroscience.
[130] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[131] S. Ferreira,et al. Amyloid-β Peptide Oligomers Disrupt Axonal Transport through an NMDA Receptor-Dependent Mechanism That Is Mediated by Glycogen Synthase Kinase 3β in Primary Cultured Hippocampal Neurons , 2010, The Journal of Neuroscience.
[132] S. Kanba,et al. Insulin resistance is associated with the pathology of Alzheimer disease , 2010, Neurology.
[133] T. Montine,et al. PGH2‐derived levuglandin adducts increase the neurotoxicity of amyloid β1–42 , 2006, Journal of neurochemistry.
[134] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[135] C. Herron,et al. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. , 2001, Journal of neurophysiology.
[136] W. K. Cullen,et al. Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization , 2008, The Journal of Neuroscience.
[137] S. M. de la Monte,et al. Insulin resistance and Alzheimer's disease. , 2009, BMB reports.
[138] Steven Mennerick,et al. Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.
[139] D. Selkoe,et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.
[140] C. Cotman,et al. β-Amyloid impairs axonal BDNF retrograde trafficking , 2011, Neurobiology of Aging.
[141] P. Mehta,et al. Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.
[142] K. Lee,et al. Prion protein: orchestrating neurotrophic activities. , 2010, Current issues in molecular biology.
[143] W. Klein,et al. Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo , 2011, Journal of neuroscience research.
[144] I. Weiler,et al. Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome , 2008, Proceedings of the National Academy of Sciences.
[145] John W. Gilbert,et al. Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.
[146] G. Taglialatela,et al. Amyloid‐β oligomers impair fear conditioned memory in a calcineurin‐dependent fashion in mice , 2010, Journal of neuroscience research.
[147] L. Frölich,et al. A Disturbance in the Neuronal Insulin Receptor Signal Transduction in Sporadic Alzheimer's Disease , 1999, Annals of the New York Academy of Sciences.
[148] David M Holtzman,et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. , 2005, Neuron.
[149] R. Lal,et al. Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: evidence for AβP channel‐mediated cellular toxicity , 2000 .
[150] W. K. Cullen,et al. Block of LTP in rat hippocampus in vivo by β‐amyloid precursor protein fragments , 1997 .
[151] N. Inestrosa,et al. Wnt-5a occludes Aβ oligomer-induced depression of glutamatergic transmission in hippocampal neurons , 2010, Molecular Neurodegeneration.
[152] Ronald D. Vale,et al. Single-Molecule Microscopy Reveals Plasma Membrane Microdomains Created by Protein-Protein Networks that Exclude or Trap Signaling Molecules in T Cells , 2005, Cell.
[153] W. Klein,et al. Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.
[154] C. Finch,et al. Purification and characterization of brain clusterin. , 1994, Biochemical and biophysical research communications.
[155] I. Sponne,et al. Apoptotic Neuronal Cell Death Induced by the Non-fibrillar Amyloid-β Peptide Proceeds through an Early Reactive Oxygen Species-dependent Cytoskeleton Perturbation* , 2003, The Journal of Biological Chemistry.
[156] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[157] C. Mirkin,et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[158] J. Busciglio,et al. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta , 2009, Proceedings of the National Academy of Sciences.
[159] L. Frölich,et al. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. , 2009, Journal of Alzheimer's disease : JAD.
[160] W. Klein,et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[161] Y. Christen,et al. Amyloid-β-Induced Pathological Behaviors Are Suppressed by Ginkgo biloba Extract EGb 761 and Ginkgolides in Transgenic Caenorhabditis elegans , 2006, The Journal of Neuroscience.
[162] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[163] L. Juliano,et al. Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling* , 2008, Journal of Biological Chemistry.
[164] Bernardo L Sabatini,et al. Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.
[165] M. Ehlers,et al. Syntaxin-4 Defines a Domain for Activity-Dependent Exocytosis in Dendritic Spines , 2010, Cell.
[166] A. Gonzalo-Ruiz,et al. Soluble oligomeric forms of beta-amyloid (Aβ) peptide stimulate Aβ production via astrogliosis in the rat brain , 2010, Experimental Neurology.
[167] H. Schoemaker,et al. Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies , 2010, The Journal of Neuroscience.
[168] C. Bonde,et al. The metabotropic glutamate receptor agonist 1S,3R-ACPD stimulates and modulates NMDA receptor mediated excitotoxicity in organotypic hippocampal slice cultures , 2001, Brain Research.
[169] C. Bagni. On BC1 RNA and the fragile X mental retardation protein , 2008, Proceedings of the National Academy of Sciences.
[170] O. Vitolo,et al. Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[171] Rie Teraoka,et al. A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.
[172] Fabiana A. Caetano,et al. Amyloid‐beta oligomers increase the localization of prion protein at the cell surface , 2011, Journal of neurochemistry.
[173] D. Porte,et al. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats , 1990, Peptides.
[174] W. K. Cullen,et al. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. , 1997, Neuroreport.
[175] D. Selkoe,et al. Small non-fibrillar assemblies of amyloid β-protein bearing the Arctic mutation induce rapid neuritic degeneration , 2005, Neurobiology of Disease.
[176] H. Wiśniewski,et al. Non‐Fibrillar β‐Amyloid Protein is Associated with Smooth Muscle Cells of Vessel Walls in Alzheimer Disease , 1994, Journal of neuropathology and experimental neurology.
[177] Lei Chang,et al. Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer’s disease drug candidate screening , 2007, Journal of Molecular Neuroscience.
[178] R. V. Van Duyne,et al. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. , 2005, Journal of the American Chemical Society.
[179] R. Lal,et al. Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[180] W. A. Pedersen,et al. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease , 2004, Neurobiology of Disease.
[181] J. Wands,et al. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. , 2005, Journal of Alzheimer's disease : JAD.
[182] B. Strooper,et al. The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.
[183] D. Selkoe,et al. Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.
[184] F. Nicoletti,et al. β-Amyloid Monomers Are Neuroprotective , 2009, The Journal of Neuroscience.
[185] W. Klein,et al. Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.
[186] P. Keller,et al. Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .
[187] Hollis T. Cline,et al. Insulin Receptor Signaling Regulates Synapse Number, Dendritic Plasticity, and Circuit Function In Vivo , 2008, Neuron.
[188] J. J. Dougherty,et al. β-Amyloid Regulation of Presynaptic Nicotinic Receptors in Rat Hippocampus and Neocortex , 2003, The Journal of Neuroscience.
[189] Shaomin Li,et al. Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake , 2009, Neuron.
[190] F. Sun,et al. Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of β-secretase activation and β-amyloid generation in rat brains , 2009, Neuroscience.
[191] D. Butterfield,et al. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. , 2001, Current medicinal chemistry.
[192] D. Selkoe,et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.
[193] James J. Hickman,et al. A New Target for Amyloid Beta Toxicity Validated by Standard and High-Throughput Electrophysiology , 2010, PloS one.
[194] R. Martins,et al. Apolipoprotein E promotes the binding and uptake of β-amyloid into Chinese hamster ovary cells in an isoform-specific manner , 1999, Neuroscience.
[195] K. Jellinger,et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.
[196] D. Graham,et al. A Neprilysin Polymorphism and Amyloid-β Plaques after Traumatic Brain Injury , 2009 .
[197] G. D. Stewart,et al. Genetic linkage map of human chromosome 21. , 1988, Genomics.
[198] C. Carlsson,et al. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[199] E. Rojas,et al. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[200] L. Partridge,et al. Insulin/IGF-like signalling, the central nervous system and aging. , 2009, The Biochemical journal.
[201] E. Mufson,et al. Decreased Brain-Derived Neurotrophic Factor Depends on Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer's Disease , 2009, The Journal of Neuroscience.
[202] S. Ferreira,et al. Formation of Soluble Oligomers and Amyloid Fibrils with Physical Properties of the Scrapie Isoform of the Prion Protein from the C-terminal Domain of Recombinant Murine Prion Protein mPrP-(121–231)* , 2006, Journal of Biological Chemistry.
[203] M. Rowan,et al. Alzheimer's Disease Brain-Derived Amyloid-β-Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein , 2011, The Journal of Neuroscience.
[204] D. Selkoe. Amyloid β protein precursor and the pathogenesis of Alzheimer's disease , 1989, Cell.
[205] C. Finch,et al. Self-assembly of Aβ1-42 into globular neurotoxins , 2003 .
[206] M. Michikawa,et al. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. , 2009, The American journal of pathology.
[207] S. Ferreira,et al. Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts , 2007, Progress in Neurobiology.
[208] P. Greengard,et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. , 2002, The American journal of pathology.
[209] F. Baas,et al. Abeta 1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. , 2007, Antioxidants & redox signaling.
[210] T. Kihara,et al. Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. , 2006, Biochemical and biophysical research communications.
[211] R. Vassar,et al. The Role of Amyloid Precursor Protein Processing by BACE1, the β-Secretase, in Alzheimer Disease Pathophysiology* , 2008, Journal of Biological Chemistry.
[212] T. Nabeshima,et al. Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse , 2011, Molecular Neurodegeneration.
[213] M. Kirkitadze,et al. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[214] D. Graham,et al. A neprilysin polymorphism and amyloid-beta plaques after traumatic brain injury. , 2009, Journal of neurotrauma.
[215] Nick C Fox,et al. Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .
[216] D. Holtzman,et al. Acute stress increases interstitial fluid amyloid-β via corticotropin-releasing factor and neuronal activity , 2007, Proceedings of the National Academy of Sciences.
[217] N. Inestrosa,et al. Role of the Wnt receptor Frizzled-1 in presynaptic differentiation and function , 2009, Neural Development.
[218] Mark F Bear,et al. The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.
[219] C. Hetz,et al. Amyloid β-peptide oligomers stimulate RyR-mediated Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF. , 2011, Antioxidants & redox signaling.
[220] A. Palmeri,et al. Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus , 2008, The Journal of Neuroscience.
[221] M. Rowan,et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. , 2005, Biochemical Society transactions.
[222] D. Selkoe,et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. , 1992, Nature.
[223] Ashley I. Bush,et al. Therapeutics for Alzheimer’s disease based on the metal hypothesis , 2008, Neurotherapeutics.
[224] J. Wands,et al. Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.
[225] Rosemary O’Connor,et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling , 2010, Neurobiology of Aging.
[226] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[227] R. Tanzi,et al. The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.
[228] J. De Keyser,et al. D1-dopamine receptor abnormality in frontal cortex points to a functional alteration of cortical cell membranes in Alzheimer's disease. , 1990, Archives of neurology.
[229] W. Klein,et al. Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. , 2009, Toxicology and applied pharmacology.
[230] D. Selkoe,et al. Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation , 1996, Neurobiology of Disease.
[231] R. Malinow,et al. The prion protein as a receptor for amyloid-β , 2010, Nature.
[232] A D Roses,et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[233] W. Engel,et al. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers , 2010, Acta Neuropathologica.
[234] P. Livrea,et al. Soluble β-Amyloid1-40 Induces NMDA-Dependent Degradation of Postsynaptic Density-95 at Glutamatergic Synapses , 2005, The Journal of Neuroscience.
[235] F. LaFerla,et al. Aβ inhibits the proteasome and enhances amyloid and tau accumulation , 2008, Neurobiology of Aging.
[236] O. Forlenza,et al. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease , 2008, Psychopharmacology.
[237] Carl W. Cotman,et al. In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.
[238] G. Glenner,et al. Immunohistochemical evidence for the derivation of a peptide ligand from the amyloid beta-protein precursor of Alzheimer disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[239] W. Klein,et al. Amyloid-β Triggers the Release of Neuronal Hexokinase 1 from Mitochondria , 2010, PloS one.
[240] C. Finch,et al. Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.
[241] A. Michelucci,et al. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-β , 2009, Journal of Neuroimmunology.
[242] B. Yankner,et al. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[243] T. Morgan,et al. Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies , 2001, Journal of neurochemistry.
[244] K. Hsu,et al. Insulin rescues amyloid β-induced impairment of hippocampal long-term potentiation , 2009, Neurobiology of Aging.
[245] S. Woods,et al. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. , 2000, Diabetes.
[246] W. Klein. Cytotoxic Intermediates in the Fibrillation Pathway: Aβ Oligomers in Alzheimer’s Disease as a Case Study , 2006 .
[247] A. García-Osta,et al. Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau Pathology , 2010, Neuropsychopharmacology.
[248] G. Glenner,et al. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.
[249] W. Klein,et al. Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ* , 2009, The Journal of Biological Chemistry.
[250] G. Schellenberg,et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.
[251] R. Hepler,et al. Solution state characterization of amyloid beta-derived diffusible ligands. , 2006, Biochemistry.
[252] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[253] D. Alkon,et al. Role of insulin and insulin receptor in learning and memory , 2001, Molecular and Cellular Endocrinology.
[254] J. Wands,et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. , 2005, Journal of Alzheimer's disease : JAD.
[255] Weiming Xia,et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.
[256] J. Marx. Fresh Evidence Points to an Old Suspect: Calcium , 2007, Science.
[257] E. Mandelkow,et al. Tau in Alzheimer's disease. , 1998, Trends in cell biology.
[258] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[259] Kristen M Harris,et al. Dendritic Spine Pathology: Cause or Consequence of Neurological Disorders? , 2002, Brain Research Reviews.
[260] K. Hsu,et al. Insulin Stimulates Postsynaptic Density-95 Protein Translation via the Phosphoinositide 3-Kinase-Akt-Mammalian Target of Rapamycin Signaling Pathway* , 2005, Journal of Biological Chemistry.
[261] Julie R. Leitz,et al. Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.
[262] Xiaohua Douglas Zhang,et al. Inhibition of Calcineurin-mediated Endocytosis and α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Prevents Amyloid β Oligomer-induced Synaptic Disruption , 2009, The Journal of Biological Chemistry.
[263] O. Vitolo,et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. , 2004, The Journal of clinical investigation.
[264] J. Wands,et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.
[265] S. Nicolaidis,et al. Basal and hyperinsulinemia-induced immunoreactive hypothalamic insulin changes in lean and genetically obese Zucker rats revealed by microdialysis , 1993, Brain Research.
[266] B. Kriem,et al. Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of the amyloid‐β peptide , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[267] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[268] B. Oostra,et al. The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses , 2003, Cell.
[269] M. Lambert,et al. Intraneuronal amyloid-beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo , 2011, Alzheimer's & Dementia.
[270] M. Ohno,et al. Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.
[271] H. Vinters,et al. β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.
[272] Shao-Jun Tang,et al. Activity-dependent Synaptic Wnt Release Regulates Hippocampal Long Term Potentiation* , 2006, Journal of Biological Chemistry.
[273] D. Diamond,et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes , 2001, Brain Research.
[274] W. Klein,et al. N‐Methyl‐d‐aspartate receptors are required for synaptic targeting of Alzheimer’s toxic amyloid‐β peptide oligomers , 2010, Journal of neurochemistry.
[275] J. Wands,et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.
[276] K. Herrup,et al. Aβ Oligomers Induce Neuronal Cell Cycle Events in Alzheimer's Disease , 2008, The Journal of Neuroscience.
[277] I. Izquierdo,et al. Physiology of the prion protein. , 2008, Physiological reviews.
[278] Shaomin Li,et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.
[279] W. Klein,et al. Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.
[280] Brett Chromy,et al. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.
[281] Xin Wu,et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.
[282] W. Klein,et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. , 2006, The Journal of biological chemistry.
[283] M. Reger,et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. , 2008, Neurology.
[284] K. Reymann,et al. Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors , 2011, Neurobiology of Aging.
[285] C. Finch,et al. Self-assembly of Abeta(1-42) into globular neurotoxins. , 2003, Biochemistry.
[286] D. Selkoe,et al. Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. , 1987, Science.
[287] C. Robinson,et al. Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. , 2009, Nature chemistry.
[288] Jens C. Brüning,et al. The role of insulin receptor signaling in the brain , 2005, Trends in Endocrinology & Metabolism.